Leerink Partnrs Has Negative View of Arvinas FY2025 Earnings

Arvinas, Inc. (NASDAQ:ARVN) – Stock analysts at Leerink Partnrs reduced their FY2025 earnings per share estimates for Arvinas in a research report issued on Tuesday, November 19th. Leerink Partnrs analyst A. Berens now anticipates that the company will post earnings per share of ($2.98) for the year, down from their previous estimate of ($2.85). The consensus estimate for Arvinas’ current full-year earnings is ($3.32) per share. Leerink Partnrs also issued estimates for Arvinas’ FY2026 earnings at ($3.64) EPS and FY2027 earnings at $1.38 EPS.

ARVN has been the topic of several other reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arvinas in a report on Monday, September 9th. Oppenheimer cut their price objective on shares of Arvinas from $50.00 to $40.00 and set an “outperform” rating on the stock in a report on Thursday, October 31st. HC Wainwright restated a “buy” rating and set a $87.00 target price on shares of Arvinas in a report on Thursday, October 31st. Stephens began coverage on Arvinas in a research report on Monday, November 18th. They issued an “overweight” rating and a $55.00 price target for the company. Finally, BMO Capital Markets dropped their price objective on Arvinas from $90.00 to $88.00 and set an “outperform” rating on the stock in a research report on Wednesday. One analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Arvinas currently has a consensus rating of “Moderate Buy” and an average target price of $61.08.

Arvinas Stock Performance

Shares of NASDAQ:ARVN opened at $25.86 on Friday. The firm’s 50 day simple moving average is $25.63 and its 200-day simple moving average is $27.05. Arvinas has a one year low of $21.17 and a one year high of $53.08. The firm has a market cap of $1.78 billion, a PE ratio of -5.48 and a beta of 1.96.

Arvinas (NASDAQ:ARVN) last announced its quarterly earnings data on Wednesday, October 30th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.88) by $0.20. The firm had revenue of $102.40 million during the quarter, compared to the consensus estimate of $60.56 million. The firm’s revenue for the quarter was up 196.0% on a year-over-year basis. During the same period in the previous year, the business earned ($1.18) EPS.

Hedge Funds Weigh In On Arvinas

Several hedge funds and other institutional investors have recently modified their holdings of ARVN. Vanguard Group Inc. grew its stake in Arvinas by 29.9% during the 1st quarter. Vanguard Group Inc. now owns 6,299,556 shares of the company’s stock valued at $260,046,000 after purchasing an additional 1,448,166 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of Arvinas by 14.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 4,368,418 shares of the company’s stock worth $180,329,000 after purchasing an additional 536,295 shares during the period. FMR LLC lifted its holdings in shares of Arvinas by 7.6% during the third quarter. FMR LLC now owns 2,883,604 shares of the company’s stock worth $71,023,000 after purchasing an additional 204,317 shares during the period. Braidwell LP boosted its position in Arvinas by 148.3% in the third quarter. Braidwell LP now owns 1,284,472 shares of the company’s stock valued at $31,637,000 after buying an additional 767,242 shares during the last quarter. Finally, ArrowMark Colorado Holdings LLC increased its holdings in Arvinas by 1.4% in the 3rd quarter. ArrowMark Colorado Holdings LLC now owns 1,244,450 shares of the company’s stock worth $30,651,000 after buying an additional 17,723 shares during the period. 95.19% of the stock is owned by hedge funds and other institutional investors.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.